Lv2
198 积分 2026-08-06 加入
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer
1小时前
待确认
Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
23天前
已完结
Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early recurrence
23天前
已完结
A multimodal atlas of hepatocellular carcinoma reveals convergent evolutionary paths and ‘bad apple’ effect on clinical trajectory
23天前
已完结
Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma
23天前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
23天前
已完结
NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy
23天前
已完结
Biomarkers for immunotherapy of hepatocellular carcinoma
23天前
已完结
Personalized MRD Assessment in Perisurgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma
25天前
已完结
Spatial immune scoring system predicts hepatocellular carcinoma recurrence
25天前
已完结
皖公网安备34019202002308
